2022 Venom Evolution, Function and Biomedical Applications GRC/GRS

2022 毒液进化、功能和生物医学应用 GRC/GRS

• 批准号: 10391650
• 负责人: Mande N. Holford
• 金额: $ 3万
• 依托单位: GORDON RESEARCH CONFERENCES
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-12-01 至 2022-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10391650
• 关键词: Address; Animals; Anticoagulation; Applied Research; Area; Basic Science; Biological Models; Biology; Biomedical Research; Biotechnology; Breathing; Captopril; Categories; Collaborations; Communication; Communities; Complex; Coronary; Coupled; Development; Diabetes Mellitus; Discipline; Ecology; Economics; Epilepsy; Evolution; Fostering; Future; Gender; General Population; Genomics; Goals; Health; Human; Human Pathology; Hypertension; Iceberg; Impairment; Industry; Ion Channel; Ion Channel Gating; Knowledge; Life; Ligands; Link; Manuscripts; Medicine; Methodology; Molecular; Molecular Structure; Molecular Target; National Center for Complementary and Integrative Health; Natural Sciences; Outcome; Pain; Pain management; Participant; Peptides; Pharmaceutical Preparations; Pharmacology; Physiological; Postdoctoral Fellow; Predatory Behavior; Prevention strategy; Protein Engineering; Proteomics; Publications; Research; Route; Science; Scientist; Societies; Source; Study models; Syndrome; Targeted Toxins; Technology; Therapeutic; Time; Toxin; Translating; Trees; Venoms; World Health Organization; bivalirudin; cohesion; drug development; drug discovery; early-career faculty; economic impact; eptifibatide; exenatide; frontier; global health; graduate student; health economics; human disease; innovation; interdisciplinary approach; meetings; neglected tropical diseases; non-opioid analgesic; novel; novel therapeutics; programs; receptor; research and development; response; socioeconomics; symposium; therapeutic development; tirofiban; tool; translational applications; voltage; ziconotide

Summary/Abstract Animal venoms are among the most complex natural secretions known, comprising a mixture of bioactive compounds often referred to as toxins. Despite their complexity, the molecular structure and targets of toxins, which include receptors and voltage- and ligand-gated ion channels, are relatively conserved throughout the animal kingdom. These features make venom an extremely successful evolutionary innovation whose components are ideal candidates for discovery and development of therapeutics to treat a wide range of human pathologies. Currently, six venom-derived peptides are commercially available drugs: ziconotide for pain; exenatide for diabetes; bivalirudin for anticoagulation; captopril for hypertension; and eptifibatide and tirofiban for coronary syndrome. Venom research is growing exponentially, as evidenced by the increase in venom publications, symposia, biomedical applications and biotech startup companies, leading to important socio- economic impacts on society. As a consequence, the World Economic Forum recently designated Venomics as one of the four most promising frontiers of science, and the World Health Organization classified snakebite as a “Category A Neglected Tropical Disease” and launched a global strategy for prevention and control of snakebite envenoming. Yet, the full potential of venom remains untapped due to a lack of knowledge on many venomous animals and a scarcity of opportunities to create a cohesive research community focused on the diversity of venom. Venom occurs so broadly across the animal tree of life that no single conference links experts in the basic and applied sciences of venomous animals to those investigating the physiological and pharmacological applications of venom. The 2022 Gordon Research Conference and Seminar on Venom Evolution, Function and Biomedical Applications (Venoms-GRC/GRS) aims to overcome these hurdles by coalescing an interdisciplinary group of academic and industry professionals to address venom as both a global health problem and a route to innovation in health solutions, including alternative, non-opioid pain management strategies. Our goals are to evaluate needs and challenges pertaining to drug discovery and development, identify future goals for venom research that will enable the field to grow and impact biomedical research and drug development and, via a special issue of manuscripts from collaborations fostered at the conference, disseminate innovative future directions in the venom field. The conference chairs are making significant efforts to invite a culturally, ethnically, and gender diverse group of 150 established and early-career faculty, postdoctoral fellows, and graduate students to the 2022 Venoms-GRC/GRS. Our program will foster a community of experts focused on complementary and integrative topics in venom drug discovery and development – key issues that are relevant to NCCIH.

总结/摘要 动物毒液是已知的最复杂的天然分泌物之一，包括生物活性物质的混合物。 通常被称为毒素的化合物。尽管它们很复杂，毒素的分子结构和目标， 包括受体和电压-和配体-门控离子通道，在整个细胞中相对保守。 动物王国这些特征使毒液成为一种极其成功的进化创新， 组分是发现和开发治疗多种人类疾病的治疗剂的理想候选物。 病理学目前，六种毒液衍生肽是市售药物：用于疼痛的齐考诺肽; 用于糖尿病的依西他滨;用于抗凝的比伐卢定;用于高血压的卡托普利;以及依替巴肽和替罗非班 治疗冠心病毒液的研究呈指数级增长，毒液的增加就证明了这一点 出版物，研讨会，生物医学应用和生物技术创业公司，导致重要的社会， 对社会的经济影响。因此，世界经济论坛最近将Venomics指定为 四个最有前途的科学前沿之一，世界卫生组织将蛇咬伤归类为 “A类被忽视的热带病”，并启动了预防和控制 毒蛇咬伤然而，由于缺乏对许多毒素的了解， 有毒的动物和机会的稀缺，以建立一个有凝聚力的研究社区，重点是 毒液的多样性毒液在动物生命树中广泛存在，没有一个会议能将专家们联系起来。 在有毒动物的基础和应用科学中， 毒液的药理学应用2022年戈登研究会议和毒液研讨会 进化，功能和生物医学应用（毒液-GRC/GRS）旨在克服这些障碍， 联合一个跨学科的学术和行业专业人士小组，以解决毒液作为一个全球性的 健康问题和健康解决办法创新途径，包括替代性非阿片类药物疼痛管理 战略布局我们的目标是评估与药物发现和开发有关的需求和挑战， 确定毒液研究的未来目标，使该领域能够发展并影响生物医学研究， 药物开发，并通过会议上促进的合作手稿特刊， 传播毒液领域的创新未来方向。会议主席们正在做出重大努力， 邀请一个文化，种族和性别多元化的150名既定和早期职业教师， 博士后研究员和研究生到2022毒液-GRC/GRS。我们的计划将培养一个 专家社区专注于毒液药物发现的互补和综合主题， 发展-与国家儿童健康协调委员会有关的关键问题。